4//SEC Filing
Smith Lillian 4
Accession 0001593968-23-000583
CIK 0001737287other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 6:43 PM ET
Size
5.0 KB
Accession
0001593968-23-000583
Insider Transaction Report
Form 4
Smith Lillian
VP, Corporate Counsel
Transactions
- Award
Common Stock
2023-04-01+56,545→ 140,390 total
Footnotes (1)
- [F1]Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001971448
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 6:43 PM ET
- Size
- 5.0 KB